The War on Drugs: How KSR v. Teleflex and Merck v. Integra Continue the Erosion of Pharmaceutical Patent Protection
› ›
Linked as:Extract
The War on Drugs: How KSR v. Teleflex and Merck v. Integra Continue the Erosion of Pharmaceutical Patent Protection
No longer available (Autolink)
See the full content of this document
This document cites
- US Code - 35 U.S.C. § 103 Conditions For Patentability; Non-Obvious Subject Matter
- US Code - 35 U.S.C. § 271 Infringement of Patent
- US Code - 35 U.S.C. § 281 Remedy For Infringement of Patent
- Code of Federal Regulations - Date of approval of a 505(b)(2) application or ANDA
- Matthewson v The Scottish Ministers
